← Leaderboards
Elia J Duh
Johns Hopkins University
$12,153,743
Attributed
$12,153,743
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,153,743 · 7
By mechanism
R01$10,960,609 · 5
K08$702,634 · 1
R03$490,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- David E. Levin$11,832,404
- Neil M Bressler$8,115,452
- Peter Louis Gehlbach$2,476,888
- King-Wai Yau$28,664,002
- Aaron W James$6,457,381
Others in their field
Top investigators on “Blindness”
- Randall J Bateman · Washington University$137,189,188
- John M Lachin · George Washington University$122,970,601
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- Beth Baseler · Leidos Biomedical Research, Inc.$111,479,515
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$96,562,493
Research focus
BlindnessRetinaRegulationLeadRetinal DiseasesRetinal NeovascularizationHypoxiaPathologicInflammatoryOxidative StressRetinalNovel TherapeuticsResponsePlayDiabetic RetinopathyGrowth FactorInsightTranscription FactorOxygenCell TypeIschemiaBlood VesselsDeveloped CountriesCells
Grant awards (34)
Soluble guanylate cyclase in diabetic retinopathy$473,552
R01 · FY2025 · EY · contact PI
Reparative angiogenesis in ischemic retinopathy$409,375
R01 · FY2025 · EY · contact PI
Soluble guanylate cyclase in diabetic retinopathy$473,552
R01 · FY2024 · EY · contact PI
Reparative angiogenesis in ischemic retinopathy$409,375
R01 · FY2024 · EY · contact PI
Role of Nrf2 in retinal vascularization and ROP$397,093
R01 · FY2021 · EY · contact PI
Regulation of diabetic retinopathy by Nrf2$456,335
R01 · FY2020 · EY · contact PI
Role of Nrf2 in retinal vascularization and ROP$409,375
R01 · FY2020 · EY · contact PI
Regulation of diabetic retinopathy by Nrf2$456,335
R01 · FY2019 · EY · contact PI
Role of Nrf2 in retinal vascularization and ROP$409,375
R01 · FY2019 · EY · contact PI
Regulation of diabetic retinopathy by Nrf2$456,335
R01 · FY2018 · EY · contact PI
Role of Nrf2 in retinal vascularization and ROP$409,271
R01 · FY2018 · EY · contact PI
Regulation of diabetic retinopathy by Nrf2$456,335
R01 · FY2017 · EY · contact PI
Role of Nrf2 in retinal vascularization and ROP$408,542
R01 · FY2017 · EY · contact PI
Regulation of diabetic retinopathy by Nrf2$456,335
R01 · FY2016 · EY · contact PI
Role of Nrf2 in retinal vascularization and ROP$396,900
R01 · FY2015 · EY · contact PI
Regulation of diabetic retinopathy by Nrf2$447,697
R01 · FY2014 · EY · contact PI
Role of Nrf2 in retinal vascularization and ROP$396,900
R01 · FY2014 · EY · contact PI
Regulation of diabetic retinopathy by Nrf2$433,992
R01 · FY2013 · EY · contact PI
Role of Nrf2 in retinal vascularization and ROP$384,750
R01 · FY2013 · EY · contact PI
Regulation of diabetic retinopathy by Nrf2$456,834
R01 · FY2012 · EY · contact PI
Role of Nrf2 in retinal vascularization and ROP$405,000
R01 · FY2012 · EY · contact PI
Regulation of diabetic retinopathy by Nrf2$142,004
R01 · FY2012 · EY · contact PI
Role and regulation of MEF2C in retinal angiogenesis$350,698
R01 · FY2011 · EY · contact PI
Role and regulation of MEF2C in retinal angiogenesis$365,310
R01 · FY2010 · EY · contact PI
Role and regulation of MEF2C in retinal angiogenesis$369,000
R01 · FY2009 · EY · contact PI
Role and regulation of MEF2C in retinal angiogenesis$361,620
R01 · FY2008 · EY · contact PI
Role and regulation of MEF2C in retinal angiogenesis$368,719
R01 · FY2007 · EY · contact PI
Inhibition of CNV using a transgenic PEDF model$163,500
R03 · FY2004 · EY
GENE EXPRESSION CHANGES IN RETINAL NEOVASCULARIZATION$188,841
K08 · FY2003 · EY
Inhibition of CNV using a transgenic PEDF model$163,500
R03 · FY2003 · EY
GENE EXPRESSION CHANGES IN RETINAL NEOVASCULARIZATION$184,128
K08 · FY2002 · EY
Inhibition of CNV using a transgenic PEDF model$163,500
R03 · FY2002 · EY
GENE EXPRESSION CHANGES IN RETINAL NEOVASCULARIZATION$166,869
K08 · FY2001 · EY
GENE EXPRESSION CHANGES IN RETINAL NEOVASCULARIZATION$162,796
K08 · FY2000 · EY